AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04942171
Drug: Medical therapy group
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Use of beta-blockers or calcium channel blockers for pulse rate control~2. Antiarrhythmic drugs are administered to patients with highly symptomatic atrial fibrillation symptoms even after pulse rate control.~3. If symptoms are not controlled even with antiarrhythmic drugs, electrical conversion to restore sinus rhythm.~4. To prevent cerebral infarction, maintain optimal anticoagulant therapy according to the risk score for cerebral infarction.~5. Conduct a questionnaire on cognitive function and emotion before and 12 months after the procedure
Trial: NCT06295432
Drug: DZD9008+AZD4205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
Trial: NCT06792422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an oral placebo once daily.~1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)~2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)~3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)
Trial: NCT06787339
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 650mg/m2, bid, p.o for 1 year
Trial: NCT06443775
Drug: Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Drops
Trial: NCT04337099
Drug: MBM-02 (Tempol)
RxNorm normalized name: SUS SCROFA TEMPORAL LOBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Trial: NCT06765902
Drug: M-CENK
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.
Trial: NCT06765252
Drug: Capecitabine-based chemotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.
Trial: NCT06795776
Drug: Eschscholzia tablets
RxNorm normalized name: Eschscholzia californica extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will be provided as swallowable Eschscholzia tablets (1.0 g) containing 0.503g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material.
Trial: NCT06795776
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants.
Trial: NCT06769113
Drug: HLX43 DOSE 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Trial: NCT06769113
Drug: HLX43 DOSE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Trial: NCT06474533
Drug: Fluorethyltyrosine (18-F)
RxNorm normalized name: Fluorethyltyrosine (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV)
Trial: NCT06564818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05028387
Drug: medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical abortion
Trial: NCT06483789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo will be supplied as a tablet.
Trial: NCT06555328
Drug: CSU lower dose treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSU lower dose treatment
Trial: NCT04997525
Drug: Estradiol Tablets
RxNorm normalized name: Estradiol Tablets
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined with progesterone
Trial: NCT05026125
Drug: Remifentanil Injection
RxNorm normalized name: remifentanil Injection
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Trial: NCT05026125
Drug: Remifentanil Injection plus 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Trial: NCT04994132
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT06746870
Drug: IMM2510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion
Trial: NCT05155306
Drug: BI 1358894, intended Commercial Formulation (iCF) (T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning
Trial: NCT06019728
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet or solution; Oral
Trial: NCT05477589
Drug: busulfan, cyclophosphamide and melphalan, BuCyMel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
Trial: NCT06100822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg capsules of placebo pills
Trial: NCT05082974
Drug: OC-01 (varenicline 0.6mg/ml) nasal spray
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
Trial: NCT05082974
Drug: Placebo (vehicle) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) nasal spray \[control\]
Trial: NCT05116774
Drug: BCX9930
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally twice daily
Trial: NCT06756828
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3months melatonin
Trial: NCT06759948
Drug: GC012F injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows:~1. Dose group 1: 1 × 10\^5/kg;~2. Dose group 2: 2 × 10\^5/kg;~3. Dose group 3: 3 × 10\^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10\^5 × 70 kg.
Trial: NCT06418061
Drug: IBI3005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
Trial: NCT04880564
Drug: CN1, 0.5mg/kg and CN401, 400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
Trial: NCT04880564
Drug: CN1, 1mg/kg and CN401, 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
Trial: NCT04880564
Drug: CN1, 1mg/kg and CN401, 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Trial: NCT04880564
Drug: CN1, 3mg/kg and CN401, 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Trial: NCT04880564
Drug: CN1, 10mg/kg and CN401, 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Trial: NCT05375903
Drug: UGN-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).
Trial: NCT06754891
Drug: TQH3906 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQH3906 is an allosteric inhibitor targeting kinase.
Trial: NCT06764966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Once Daily along with previously prescribed Non Selective Beta Blocker
Trial: NCT06734975
Drug: Superior laryngeal nerve block - Placebo (saline)
RxNorm normalized name: ACS22Q55 NERVE BLOCK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
Trial: NCT06739473
Drug: CEUS or Contrast enhanced Ultrasound
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia
Trial: NCT06736912
Drug: IN-114199 2.5mg or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN-114199 2.5mg or placebo (1 Tablet, QD)
Trial: NCT05919615
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride normal saline
Trial: NCT05851027
Drug: QL0911
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
Trial: NCT06759298
Drug: matched placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo gtoup will recieve matched placebo tablet
Trial: NCT06751108
Drug: Corticosteroids (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of immune checkpoint inhibitors and corticosteroids
Trial: NCT06791512
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control group will receive the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) alone.
Trial: NCT06199349
Drug: GMDTC for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Trial: NCT06581380
Drug: JK-1201I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.
Trial: NCT06740422
Drug: Xuanhuang Runtong Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.
Trial: NCT05453136
Drug: TS-142 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received repeated doses of 5 mg of TS-142 (oral tablet)
Trial: NCT05453136
Drug: TS-142 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received repeated doses of 10 mg of TS-142 (oral tablet)
Trial: NCT05453136
Drug: Placebo to TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received repeated doses of placebo to TS-142 (oral tablet)
Trial: NCT06793293
Drug: Non-steroidal anti- inflammatory drugs and antibiotics
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) only.
Trial: NCT06757153
Drug: NRG-103
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.
Trial: NCT06194617
Drug: Direct oral anticoagulant
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
Trial: NCT06761339
Drug: Prospan cough Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active comparator, Prospan Cough Syrup is a plant-based herbal medicinal product containing the active ingredient Hedera helix (ivy leaf extract), standardized to ensure consistent pharmacological efficacy. The syrup is formulated as an oral liquid preparation with a pleasant taste suitable for pediatric and adult use. The intervention involves administering 2.5 ml per dose three times daily, taken orally 30 minutes before meals, for a duration of 7 days.
Trial: NCT06763094
Drug: Calcium dobesilate (Doxium)
RxNorm normalized name: calcium dobesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is unique because Calcium Dobesilate is not a hormonal agent and does not carry the risks associated with hormonal therapies, such as potential impact on fertility or long-term endocrine effects. Additionally, it may be more suitable for patients who cannot tolerate hormonal treatments due to contraindications such as previous thrombotic events or risk factors for thrombosis.
Trial: NCT06773221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, qd, for 72 weeks
Trial: NCT06323837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match.
Trial: NCT05289037
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 oil-in-water emulsion adjuvant.
Trial: NCT04715568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets taken orally
Trial: NCT04674241
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline is administered with the same volume at the same speed as the other group.
Trial: NCT06779045
Drug: AK-1286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.
Trial: NCT05142267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Trial: NCT05013008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
Trial: NCT04760717
Drug: Spironolactone Pill
RxNorm normalized name: spironolactone Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
Trial: NCT06115733
Drug: Fruquintinib、Capecitabine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ⅰb dose exploration trial of fuquinitinib combined with capecitabine (n=6-9) :~3) Capecitabine: 1000 mg/m² orally, twice a day on days 1-21 of each cycle, 28 days for one treatment cycle.~4) Fuquinitinib: 1 to 21 days per cycle, orally, once a day, 28 days for a treatment cycle. There are two dose gradients of fuquintinib: 2mg/d, and the initial dose of 3mg/d is 2mg/d. According to the 3+3 dose climbing principle, dose exploration is carried out in the order of 2mg/d→3mg/d, as follows:~Phase II: Dose extension trial (n=47) :~The recommended dose of fuquinitinib combined with capecitabine, as determined in phase I b, continued to enroll 47 patients in the dose-expansion phase trial until the patient became intolerant of toxicity or disease progression.
Trial: NCT05874063
Drug: Thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboprophylaxis in addition of the standard chemotherapy
Trial: NCT05318794
Drug: Doxorubicin and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pressurised intraperitoneal aerosol chemotherapy
Trial: NCT05934513
Drug: GFH009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
Trial: NCT06752603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT06768255
Drug: Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT
RxNorm normalized name: Abiraterone Acetate
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone Acetate（II）
Trial: NCT06768255
Drug: Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1000 mg
Trial: NCT00929461
Drug: Lipovenoes® 10% and Omegaven®,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
Trial: NCT06263452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated sugar pill to visually look identical to the experimental condition.
Trial: NCT06768658
Drug: TAK-951 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-951 placebo-matching subcutaneous injection.
Trial: NCT05895201
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg IV over 1 hour on days +3 and +4
Trial: NCT05191004
Drug: NUV-422
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUV-422 is an investigational drug for oral dosing.
Trial: NCT06045910
Drug: ALETA-001
RxNorm normalized name: DIOSCOREA ALATA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALETA-001 will be administered intravenously (IV) every two weeks.
Trial: NCT06247995
Drug: [68Ga]Ga-NeoB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga\]Ga-NeoB serves as a radioactive imaging compound to be used for PET imaging for localization of GRPR positive lesions.
Trial: NCT06247995
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a chemotherapy drug.